Responders (R, with a decreased tumor size or SD > 6 months) had greater baseline frequencies of CD33hi classical monocytes (CD33hi cMo, p = 0.014) and CD9+ nonclassical monocytes (CD9+ nMo, p = 0.012) than non-responding (NR) patients (Fig. 4D). The gene discussed is CD9; the disease is neoplasm.